Global Cord Blood (NYSE:CO) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Global Cord Blood (NYSE:CO – Get Rating) in a report issued on Friday. The brokerage set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Price Performance

CO stock opened at $2.99 on Friday. Global Cord Blood has a 12 month low of $2.03 and a 12 month high of $5.50. The firm has a 50 day moving average of $2.99 and a two-hundred day moving average of $2.90.

Institutional Trading of Global Cord Blood

Institutional investors and hedge funds have recently modified their holdings of the company. Northern Trust Corp acquired a new stake in shares of Global Cord Blood in the second quarter worth $96,000. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Global Cord Blood in the third quarter worth $176,000. Natixis Advisors L.P. lifted its stake in shares of Global Cord Blood by 6.6% in the first quarter. Natixis Advisors L.P. now owns 189,330 shares of the medical research company’s stock worth $729,000 after buying an additional 11,709 shares during the last quarter. Finally, Moneta Group Investment Advisors LLC lifted its stake in shares of Global Cord Blood by 99,844.5% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 26,093,520 shares of the medical research company’s stock worth $77,957,000 after buying an additional 26,067,412 shares during the last quarter.

About Global Cord Blood

(Get Rating)

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.